Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25,955 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.
Cho YS, Jang TW, Kim HJ, Oh JY, Lee HK, Park HK, Ghim JL, Long NP, Park Y, Choi YK, Phuong NTT, Shin JG; Center for Personalized Precision Medicine of Tuberculosis. Cho YS, et al. Among authors: park y, park hk. J Clin Pharmacol. 2021 Dec;61(12):1567-1578. doi: 10.1002/jcph.1931. Epub 2021 Jul 26. J Clin Pharmacol. 2021. PMID: 34157153
Fitness costs of rifampicin resistance in Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the β' subunit of RNA polymerase.
Song T, Park Y, Shamputa IC, Seo S, Lee SY, Jeon HS, Choi H, Lee M, Glynne RJ, Barnes SW, Walker JR, Batalov S, Yusim K, Feng S, Tung CS, Theiler J, Via LE, Boshoff HI, Murakami KS, Korber B, Barry CE 3rd, Cho SN. Song T, et al. Among authors: park y. Mol Microbiol. 2014 Mar;91(6):1106-19. doi: 10.1111/mmi.12520. Epub 2014 Feb 26. Mol Microbiol. 2014. PMID: 24417450 Free PMC article.
Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.
Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, Follman D, Wang J, Cai Y, Goldfeder LC, Olivier KN, Xie Y, Via LE, Cho SN, Barry CE 3rd, Chen RY. Song T, et al. Among authors: park y. EBioMedicine. 2015 Oct 9;2(11):1627-33. doi: 10.1016/j.ebiom.2015.09.051. eCollection 2015 Nov. EBioMedicine. 2015. PMID: 26870788 Free PMC article. Clinical Trial.
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
Kuemmel S, Harper-Wynne C, Park YH, Franke F, de Laurentiis M, Schumacher-Wulf E, Eiger D, Heeson S, Cardona A, Özyilkan Ö, Morales-Vàsquez F, Metcalfe C, Hafner M, Restuccia E, O'Shaughnessy J. Kuemmel S, et al. Among authors: park yh. BMC Cancer. 2024 May 24;24(1):641. doi: 10.1186/s12885-024-12179-9. BMC Cancer. 2024. PMID: 38789924
25,955 results
You have reached the last available page of results. Please see the User Guide for more information.